Celgene Cancer Drug Makes Regulatory Strides In China, US
Overcoming serious safety concerns, Celgene Corp. on Monday announced that its blood cancer drug Revlimid has won approval in China, a development that came just days after the company said U.S....To view the full article, register now.
Already a subscriber? Click here to view full article